Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation

Cited by (1,000)

Items 701–800 of 1,000

1. New Frontiers for Stroke Prevention in Atrial Fibrillation
   Vinay K. Prasad, Rachel M. Kaplan, ROD S. PASSMAN · 2012 · Cerebrovascular Diseases
2. The Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER)
   Faruk Ertaş, Nihan Kahya Eren, Hasan Kaya, Alpay Arıbaş, Göksel Açar, Mehmet Kanadaşı, Hikmet Selçuk Gedik, Mustafa Oylumlu, Murat Yüksel, Mehmet Sıddık Ülgen · 2013 · Cardiology Journal
3. The Safety Risks of Innovation
   Thomas J. Moore, Curt Daniel Furberg · 2012 · JAMA
4. Managing Bleeding in Anticoagulated Patients in the Emergency Care Setting
   Charles V. Pollack · 2013 · Journal of Emergency Medicine
5. The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses
   Sam Schulman, Ammar Majeed · 2012 · Seminars in Thrombosis and Hemostasis
6. CHA 2 DS 2 -VASc score in the prediction of ischemic bowel disease among patients with atrial fibrillation: Insights from a nationwide cohort
   Wei‐Syun Hu, Cheng‐Li Lin · 2017 · International Journal of Cardiology
7. Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis
   Weiwei Xu, Shen‐Jiang Hu, Tao Wu · 2017 · Journal of Zhejiang University SCIENCE B
8. Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing
   Dimitrios T. Farmakis, Periklis A. Davlouros, Grigorios Giamouzis, George A. Giannakoulas, Athanasios G. Pipilis, Georgios K. Tsivgoulis, John Parissis · 2018 · Cardiology
9. Interventional Closure of the Left Atrial Appendage for Stroke Prevention
   Yae Matsuo, Marcus Sandri, Norman Mangner, Nicolas Majunke, Ingo Dähnert, Gerhard C Schuler, Masahiko Kurabayashi, Sven Möbius‐Winkler · 2014 · Circulation Journal
10. Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type
    Blanca Fuentes, J. Gállego, Antonio Gil-Núñez, Ana Morales, Francisco F. Purroy, Jaume Roquer, Tomás Segura, Javier Tejada, Aida Pilar Lago, Exuperio Díez‐Tejedor et al. · 2014 · Neurología (English Edition)
11. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (NICE technology appraisal guidance 90)
    Kirsty Stewart, James Walters, Jesse Dawson · 2011 · Heart
12. Antiplatelet therapy after coronary intervention in Asia and Japan
    Eri Toda, Shinya Goto · 2009 · Hämostaseologie
13. Resumption of Anticoagulation After Intracranial Hemorrhage
    Ivan Rocha Ferreira da Silva, Jennifer Ann Frontera · 2017 · Current Treatment Options in Neurology
14. Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial
    Ziad Hijazi, Paolo Verdecchia, Jonas Oldgren, Ulrika Andersson, Gianpaolo Reboldi, Giuseppe Di Pasquale, Giovanni Mazzotta, Fabio Angeli, John W. Eikelboom, Michael D. Ezekowitz et al. · 2019 · Journal of the American Heart Association
15. Factors associated with ‘caregiver burden’ for atrial fibrillation patients
    Craig Ian Coleman, Stacey M Coleman, Julie Vanderpoel, Winnie W. Nelson, J. Colby, J. M. Scholle, Jeffrey Kluger · 2012 · International Journal of Clinical Practice
16. DVT: A New Era in Anticoagulant Therapy
    Nigel Mackman, Richard Clinton Becker · 2010 · Arteriosclerosis Thrombosis and Vascular Biology
17. Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons
    Jacqueline L.Y. Chee, Xue Li Guan, J. Y. Lee, B. Dong, Sai Mun Leong, E. H. Ong, Anthony K. F. Liou, T. M. Lim · 2005 · Cellular and Molecular Life Sciences
18. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
    Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P. et al. · 2016 · European Heart Journal
19. How to prevent, treat, and overcome current clinical challenges of VTE
    Josien van Es, Elise S. Eerenberg, Pieter Willem Kamphuisen, Harry Roger Buller · 2011 · Journal of Thrombosis and Haemostasis
20. REVIEW: New Antithrombotics for Atrial Fibrillation
    Lre Bereznicki, Gregory Mark Peterson · 2010 · Cardiovascular Therapeutics
21. Which Oral Anticoagulant for Which Atrial Fibrillation Patient: Recent Clinical Trials and Evidence-Based Choices
    John A. Cairns · 2013 · Canadian Journal of Cardiology
22. The Quandary of Oral Anticoagulation in Patients With Atrial Fibrillation and Chronic Kidney Disease
    Shmuel Schwartzenberg, Eli Israel Lev, Alexander Sagie, Asher Korzets, Ran Kornowski · 2015 · The American Journal of Cardiology
23. Oral Anticoagulants – A Frequent Challenge for the Emergency Management of Acute Ischemic Stroke
    Timolaos Rizos, Solveig Horstmann, Ekkehart Jenetzky, Marcia Spindler, Christoph Gumbinger, Markus Alfred Möhlenbruch, Peter Arthur Ringleb, Werner Hacke, Roland C. Veltkamp · 2012 · Cerebrovascular Diseases
24. Risk of Gastrointestinal Bleeding with Dabigatran: A Head-to-Head Comparative Study with Rivaroxaban
    Muhammed Sherid, Humberto Sifuentes, Samian Sulaiman, Salih Samo, Husein Husein, Ruth S. Tupper, Dharma S. Thiruvaiyaru, Charles Spurr, Subbaramiah Sridhar · 2014 · Digestion
25. Combined anti-platelet therapy with aspirin and clopidogrel: Risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
    Andreas Hermann, Imanuel Dzialowski, Roland Koch, Georg Gahn · 2009 · Journal of the Neurological Sciences
26. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights
    Olga Marchenko, Estelle Russek‐Cohen, Mark S Levenson, Richard C. Zink, Michelle R Krukas-Hampel, Qi Jiang · 2017 · Therapeutic Innovation & Regulatory Science
27. Immunotherapy in antiphospholipid syndrome
    Chary López-Pedrera, Maria Angeles Aguirre, Patricia Ruiz‐Limón, C. Pérez‐Sánchez, Yolanda Jiménez, Nuria Barbarroja, María José Cuadrado · 2015 · International Immunopharmacology
28. Mechanisms of Stroke in Atrial Fibrillation
    Jose Maria Castellano, Jason S. Chinitz, Jonathan Willner, Valentı́n Fuster · 2014 · Cardiac Electrophysiology Clinics
29. Dabigatran Challenges Warfarin’s Superiority for Stroke Prevention in Atrial Fibrillation
    Neil E Schwartz, Gregory W. Albers · 2010 · Stroke
30. Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery?
    Peter B. Berger, Henry Lester Kirchner, Eric S. Wagner, Ibrahim Ismail‐Sayed, SALMA YAHYA, Charles H. Benoit, James C. Blankenship, Russell Carter, Alfred S. Casale, Sandy M. Green et al. · 2015 · Journal of Interventional Cardiology
31. Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and Dabigatran
    Stephanie A. Ross, Guillaume Paré · 2013 · Pharmacogenomics
32. Dual Antiplatelet Therapy for Coronary Artery Disease
    Cheol Whan Lee · 2015 · Circulation Journal
33. Antithrombotic Management of Atrial Fibrillation in the Elderly
    Karli Edholm, Nathan Ragle, Matthew Thomas Rondina · 2015 · Medical Clinics of North America
34. A New Score for Predicting Acute Gastrointestinal Bleeding in Patients Administered Oral Antiplatelet Drugs
    Meina Lv, Xiaochun Zheng, Tingting Wu, Wenjun Chen, Shaojun Jiang, Hongqin Zhang, Fang-da Xu, Jinhua Zhang · 2021 · Frontiers in Pharmacology
35. Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF
    Monika Kozieł, Christine Teutsch, Jonathan L. Halperin, Kenneth Jay Rothman, Hans‐Christoph Diener, Chang-Sheng Ma, Sabrina Vogel Marler, Shihai Lu, Venkatesh Kumar Gurusamy, Menno Volkert Huisman et al. · 2021 · PLoS ONE
36. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
    Mikhail S. Dzeshka, Gregory Y.H. Lip · 2014 · Trends in Cardiovascular Medicine
37. Warfarin Use in Nursing Home Residents: Results from the 2004 National Nursing Home Survey
    Parinaz K. Ghaswalla, Spencer E. Harpe, Patricia W. Slattum · 2012 · The American Journal of Geriatric Pharmacotherapy
38. Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting
    Bin Yan Wu, Kun Li, Xiaoyan Liu, Ben He · 2013 · Cardiovascular Drugs and Therapy
39. Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal
    Alexandru Burlacu, Simonetta Genovesi, David J.A. Goldsmith, Patrick Rossignol, Alberto Ortíz, Philip A. Kalra, Jolanta Małyszko, Maciej Banach, Mehmet Kanbay, Adrian Constantin Covic · 2017 · Pharmacological Research
40. Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
    Joong Hyun Park, Sang Won Han, Kyung‐Yul Lee, Hye‐Yeon Choi, Kyeongyeol Cheon, Han‐Jin Cho, Yo Han Jung, Hyungjong Park, Hyo Suk Nam, Ji Hoe Heo et al. · 2018 · Frontiers in Neurology
41. Stroke Prevention in Atrial Fibrillation
    Viwe Mtwesi, Guy Amit · 2019 · Medical Clinics of North America
42. PAR-1 antagonists: current state of evidence
    Saurav Chatterjee, Abhishek Sharma, Debabrata Mukherjee · 2012 · Journal of Thrombosis and Thrombolysis
43. Neurofilament Light Chain and Risk of Stroke in Patients With Atrial Fibrillation
    Julia Aulin, Karl Sjölin, Johan Lindbäck, Alexander Philipp Benz, John W. Eikelboom, Ziad Hijazi, Kim Kultima, Jonas Oldgren, Lars C. Wallentin, Joachim Burman et al. · 2024 · Circulation
44. Urgent Statement on Antithrombotic Therapy of Atrial Fibrillation
    Satoshi Ogawa, Masatsugu Hori · 2011 · Circulation Journal
45. Antithrombotic Medication for Cardioembolic Stroke Prevention
    Maria Àngels Font, Jerzy Krupiński, Adrià Arboix · 2011 · Stroke Research and Treatment
46. Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient
    Scott W. Yates · 2013 · International Journal of General Medicine
47. Adherence to the ABC (Atrial fibrillation Better Care) pathway in the Balkan region: the BALKAN-AF survey
    Monika Kozieł, Stefan M. Simovic, Nikola Pavlović, Aleksandar Kocijančić, Vilma Paparisto, Ljilja Musić, Elina Trendafilova, Anca Rodica Dan, Zumreta Kušljugić, Gheorghe‐Andrei Dan et al. · 2020 · Polskie Archiwum Medycyny Wewnętrznej
48. Atrial Fibrillation
    Laura J. Bontempo, Eric Goralnick · 2011 · Emergency Medicine Clinics of North America
49. Atrial fibrillation, stroke, and quality of life
    Jason S. Chinitz, Jose Maria Castellano, Jason Ciril Kovacic, Valentı́n Fuster · 2012 · Annals of the New York Academy of Sciences
50. Antiplatelet and Anticoagulant Therapy in Patients With Gastrointestinal Bleeding
    Majid Abdularahman Almadi, Alan N. Barkun, James M. Brophy · 2011 · JAMA
51. Direct Thrombin Inhibitors’ Potential Efficacy in Alzheimer’s Disease
    Rami Bou Khalil · 2012 · American Journal of Alzheimer s Disease & Other Dementias®
52. Pharmacological basis and clinical evidence of dabigatran therapy
    Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, Jorge Navarro‐Dorado, Abelardo Bárez, Teresa Tejerina · 2011 · Journal of Hematology & Oncology
53. Appropriate Use of Antithrombotic Medication in Canadian Patients With Nonvalvular Atrial Fibrillation
    Alan Bell, Peter L. Gross, Michael Heffernan, Yan Deschaintre, Jean-François Roux, Daniel M. Purdham, Ashfaq M Shuaib · 2016 · The American Journal of Cardiology
54. Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002–2013)
    Mi Kyoung Son, Nam-Kyoo Lim, Hyun‐Young Park · 2017 · Journal of Epidemiology
55. Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy
    Flávia Mayer, Ursula Kirchmayer, Paola Coletta, Nera Agabiti, Valeria Belleudi, Giovanna Cappai, Mirko Di Martino, Sebastian Schneeweiß, Marina Davoli, Elisabetta Patorno · 2018 · Journal of the American Heart Association
56. Stroke prevention in atrial fibrillation
    Hans‐Christoph Diener, Ralph Weber, Gregory Y.H. Lip, Stefan Hans Hohnloser · 2011 · Current Opinion in Neurology
57. Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network
    Carlo Lavalle, Luca Di Lullo, Antonio Bellasi, Claudio Ronco, Stefano Radicchia, Vincenzo Bàrbera, Gioacchino Galardo, Agostino Piro, Michele Magnocavallo, Martina Straito et al. · 2020 · Cardiorenal Medicine
58. The Impact of CHA2DS2-VASc and HAS-BLED Scores on Clinical Outcomes in the Amplatzer Amulet Study
    Giuseppe Tarantini, Gianpiero D’Amico, Boris Schmidt, Patrizio Mazzone, Sérgio Luis Berti, Sven Fischer, Juha Lund, Matteo Montorfano, Paolo Emilio Della Bella, Simon Cheung Chi Lam et al. · 2020 · JACC: Cardiovascular Interventions
59. Clinical U pdate on the M anagement of A trial F ibrillation
    Ilya M. Danelich, Brent N. Reed, Ian B. Hollis, Abigail M. Cook, Jo E. Rodgers · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
60. Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients
    Matteo Nicola Dario Di Minno, Anna Russolillo, Alessandro Di Minno, Marina Camera, Alessandro Parolari, Elena Tremoli · 2013 · Expert Opinion on Emerging Drugs
61. Effect of Ibuprofen Dose on Platelet Aggregation and Coagulation in Blood Samples From Pigs
    Wenjun Z. Martini, Rodolfo Deguzman, Cassandra M. Rodriguez, Jessica Guerra, Angela K. Martini, Anthony E. Pusateri, Michael A. Dubick · 2015 · Military Medicine
62. Atrial fibrillation in chronic kidney disease
    Luminita E. Voroneanu, Alberto Ortíz, Ionuţ Nistor, Adrian Constantin Covic · 2016 · European Journal of Internal Medicine
63. CYP2C19 Genotype and Cardiovascular Events
    Mark R. Vesely · 2012 · JAMA
64. Embedding equity, diversity and inclusion processes within clinical trials and health and social care research
    Keerti Gedela, Richard J. Wong, Suki Balendra, Sunder K. Chita, Helen Jones, Rainer Golombek, Keitumetse-Kabelo Murray · 2025 · BMJ Open
65. Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban
    Tan Ru San, Mark Y. Chan, Wee Siong Teo, Kok Foo Tang, Ng Kheng Siang, Sze Huar Lee, Ching Chi Keong · 2012 · Thrombosis
66. Net clinical benefit of edoxaban versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study
    Andrew D. Blann, Amitava Banerjee, Deirdre A. Lane, Christian Tobias Torp-Pedersen, Gregory Y.H. Lip · 2015 · International Journal of Cardiology
67. New Oral Anticoagulants in Nonvalvular Atrial Fibrillation
    Urooj Fatima, Abhishek Kulkarni, Dwight D. Stapleton, Edo Kaluski · 2016 · Clinical Cardiology
68. Indications for suboptimal low‐dose direct oral anticoagulants for non‐valvular atrial fibrillation patients
    Masahiko Umei, Mikio Kishi, Takahiro Sato, Akito Shindo, Toyoda Masayuki, Masaaki Yokoyama, Masashiro Matsushita, Satoshi Ohnishi, Masao Yamasaki · 2017 · Journal of Arrhythmia
69. New Oral Anticoagulants Versus Warfarin in Atrial Fibrillation After Early Postoperative Period in Patients With Bioprosthetic Aortic Valve
    Vito Antonio Mannacio, Luigi Mannacio, Anita Antignano, Ciro Mauro, Pasquale Mastroroberto, Francesco Musumeci, Carlo Zebele, Gabriele Iannelli · 2021 · The Annals of Thoracic Surgery
70. Clopidogrel Administration Impairs Post-Stroke Learning and Memory Recovery in Mice
    Marina Paul, Jonathan Paúl, Madeleine Hinwood, Rebecca J. Hood, Kristy Martin, Mahmoud Abdolhoseini, Sarah J. Johnson, Michael R. P. Pollack, Michael Nilsson, Frederick Rohan Walker · 2023 · International Journal of Molecular Sciences
71. Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER.
    J. Matthew Brennan, Karen P. Alexander, Amelie Wallace, Audra B Hodges, John C. Laschinger, Kent W. Jones, Sean M. O’Brien, Laura E Webb, Rachel S. Dokholyan, Eric David Peterson · 2012 · PubMed
72. Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke
    Svjetlana Šupe, Zdravka Poljaković, Tamara Božina, Josip Ljevak, Viola Macolić Šarinić, Nada Božina · 2015 · Archives of Medical Research
73. Anticoagulation Therapy for Atrial Fibrillation
    Elaine M. Hylek · 2013 · Seminars in Thrombosis and Hemostasis
74. The Association of Direct Thrombin Inhibitor Anticoagulants With Cardiac Thromboses
    Bruce L. Davidson · 2014 · CHEST Journal
75. Novel Anticoagulants in Atrial Fibrillation: A Primer for the Primary Physician
    Martina Mookadam, Fadi Elias Shamoun, Farouk Mookadam · 2015 · The Journal of the American Board of Family Medicine
76. Grado de control del tratamiento anticoagulante oral en los centros de Atención Primaria de la Comunidad de Madrid: estudio CHRONOS-TAO
    Rafael Alonso Roca, Carmen Arlene Figueroa Guerrero, Victoria Mainar de Paz, Miguel García, Luis Sánchez Perruca, Ricardo Rodríguez-Barrientos, Mariano Casado López, Ana María Pedraza-Flechas · 2014 · Medicina Clínica
77. Simple and rapid assay for effect of the new oral anticoagulant (NOAC) rivaroxaban: preliminary results support further tests with all NOACs
    Raúl Altman, Claudio Daniel González · 2014 · Thrombosis Journal
78. Development and validation of a decision aid for choosing among antithrombotic agents for atrial fibrillation
    Safoora Fatima, Anne Marie Holbrook, Sam Schulman, Steve Park, Sue Troyan, Greg Curnew · 2016 · Thrombosis Research
79. Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation
    Vivian Wing Yan Lee, Ronald Bing-Ching Tsai, I.H.I. Chow, Bryan Ping-Yen Yan, Mehmet Güngör Kaya, Jai‐Wun Park, Yat‐Yin Lam · 2016 · BMC Cardiovascular Disorders
80. Atrial fibrillation in the elderly
    A. Franken Roberto, F. Rosa Ronaldo, CM Santos Silvio · 2012 · 老年心脏病学杂志：英文版
81. Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
    Ipek Komsuoglu Celikyurt, Christoph Rudolf Meier, Michael Kühne, Beat Andreas Schaer · 2017 · Drug Safety
82. Anticoagulation in the cardiac patient: A concise review
    Elise A. Larson, David M. German, Joseph James Shatzel, Thomas G. DeLoughery · 2018 · European Journal Of Haematology
83. Hyperlipidaemia in Paediatric Patients
    Anthony S. Wierzbicki, Adie Viljoen · 2010 · Drug Safety
84. Gastrointestinal disorders and dabigatran
    Arthur W. Hoffman, Peter R. Galle · 2012 · Scandinavian Journal of Gastroenterology
85. Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol
    Jessica Kepplinger, Alexandra Prakapenia, Kristian Barlinn, Gabriele Siegert, Siegmund Gehrisch, Charlotte Zerna, Jan Beyer‐Westendorf, Volker Puetz, Heinz Reichmann, Timo Siepmann et al. · 2015 · Journal of Thrombosis and Thrombolysis
86. Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions
    Raffaele De Caterina, Elaine M. Hylek · 2011 · The American Journal of Medicine
87. Atrial Fibrillation and Congestive Heart Failure
    Sudarone Thihalolipavan, Daniel P. Morin · 2014 · Heart Failure Clinics
88. Thrombolysis in a Stroke Patient on Dabigatran Anticoagulation: Case Report and Synopsis of Published Cases
    Waltraud Pfeilschifter, Mario Abruscato, Susanne Hövelmann, Horst K.J. Baas · 2013 · Case Reports in Neurology
89. Anticoagulation-Related Intracranial Hemorrhages
    Manoj Kumar Mittal, Alejandro A. Rabinstein · 2012 · Current Atherosclerosis Reports
90. Free Fatty Acid Is Associated with Thrombogenicity in Cardioembolic Stroke
    Woo‐Keun Seo, Jin‐Man Jung, Ji Hyun Kim, Seong‐Beom Koh, Oh Young Bang, Kyungmi Oh · 2017 · Cerebrovascular Diseases
91. Antithrombotic Management in AF Patients Following Percutaneous Coronary Intervention: A European Perspective
    Antonio Greco, Claudio Laudani, Carla Rochira, Davide Capodanno · 2023 · Interventional Cardiology Reviews Research Resources
92. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin
    Taketoshi Furugohri, Yoshiyuki MORISHIMA · 2015 · Thrombosis Research
93. Stroke prevention in AF
    Gregory Y.H. Lip · 2011 · Nature Reviews Cardiology
94. Aspirin and Clopidogrel for Prevention of Ischemic Stroke
    Ruth M. Thomson, David C. Anderson · 2013 · Current Neurology and Neuroscience Reports
95. Factors associated with warfarin discontinuation, including bleeding patterns, in atrial fibrillation patients
    Dong‐Churl Suh, Jiyoon C. Choi, Jeff R. Schein, Suhyun Kim, Winnie W. Nelson · 2013 · Current Medical Research and Opinion
96. Antiplatelet therapy in prevention of cardio- and venous thromboembolic events
    Steven R. Steinhubl, John W. Eikelboom, Elaine M. Hylek, Harold L. Dauerman, Susan S. Smyth, Richard Clinton Becker · 2013 · Journal of Thrombosis and Thrombolysis
97. Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel
    Miklós Rohla, Thomas Werner Weiss, Johann Wojta, Alexander Niessner, Kurt Huber · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
98. Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis
    Ali Ali, C. Bailey, Ahmed H. Abdelhafiz · 2012 · Age and Ageing
99. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant
    Louise Brown, Christopher John Boos · 2016 · International Journal of Cardiology
100. Idarucizumab for the Reversal of Dabigatran
     Michael A. Gottlieb, Basem F. Khishfe · 2017 · Annals of Emergency Medicine